Vor Biopharma has transitioned from oncology to focus on developing telitacicept, a dual BAFF/APRIL inhibitor targeting autoimmune diseases. The company has $491.5 million in cash, providing financial stability through early 2029 and supporting upcoming Phase 3 trial results for generalized myasthenia gravis (gMG) and Sjögren’s disease. Telitacicept shows promising efficacy by inhibiting upstream B-cell pathways but faces strong competition and regulatory challenges. Vor Biopharma is considered a speculative investment with potential upside if global trials confirm Chinese results, though it carries risks due to reliance on a single drug and milestone obligations.
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against BitGo Holdings, Erasca, and First Solar. These lawsuits allege that the companies made misleading statements or failed t...
BMO has committed $500,000 over five years to the National Music Centre's Music Therapy Initiative, with matching funds from The Jim Pattison Foundation. This investment will expand music therapy programs in hospitals and community health settings ac...
The 22nd Annual Energy Innovations: LDC Gas Forum Rockies & West will be held in San Diego from August 10-12, 2026, bringing together over 250 natural gas industry professionals. The forum focuses on critical issues affecting the U.S. Rockies and Wes...
New research from Spherix Global Insights reveals that despite advances in lupus treatment, including increased use of biologics and new therapies, many patients with systemic lupus erythematosus (SLE) continue to experience persistent symptoms, freq...
As Canada enters peak summer storm season, a survey by First Onsite reveals 72% of Canadians are concerned about climate-related extreme weather like flooding, severe storms, and tornadoes. Regional concerns vary, with British Columbians fearing floo...
